DNLI - Company ID 0001714899
The table below shows Denali Therapeutics Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$131.20M | -$131.47M | -$113.62M | -$58.80M | -$72.11M | -$50.24M |
| Capital expenditure | $2.47M | $5.08M | $2.15M | $2.79M | $4.04M | $2.80M |
| Investing cash flow | $94.46M | $18.75M | -$453.19M | -$92.72M | -$117.88M | -$25.41M |
| Dividends paid | - | - | - |
Denali Therapeutics Inc. reported operating cash flow of -$412.60M for fiscal year 2025. That is down 18.7% from -$347.69M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$71.91M (FY 2016) to -$412.60M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $219.04M | -$3.76M | $500.27M | $1.60M | $1.46M | $3.82M |